Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...

Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...

Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal ...

Vir Biotechnology ( (VIR) ) has issued an update. Vir Biotechnology announced promising Phase 1 trial results for its ...

Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and ...

In a report released today, Gena Wang from Barclays assigned a Buy rating to Vir Biotechnology (VIR – Research Report), with a price target of ...

Vir Biotechnology (VIR) stock was upgraded by Morgan Stanley after the company posted trial data for two antitumor agents ...

Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of ...

JP Morgan has recently reduced Vir Biotechnology Inc (VIR) stock to Neutral rating, as announced on January 29, 2024, according to Finviz. Earlier, on September 8, 2023, BofA Securities had reduced ...

Shares of the battered biotech Vir Biotechnology were up more than 70% on Wednesday, as the company reported its first positive data since it executed a major pivot last summer. A hot stock during the ...

Vir Biotechnology announced promising results Wednesday for a pair of cancer treatments, and Vir stock catapulted by double ...

Vir Biotechnology, Inc. (Nasdaq: VIR) is experiencing a massive surge in the stock market, climbing an impressive +74.08% or $5.85 to $13.74 in Wednesday’s trading session at 12:22 PM EST. This sharp ...